Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate

Journal of Bone and Mineral Research

Volumn 25, Issue 8, 2010, Pages 1886-1894

  Seeman, Ego ^a   Delmas, Pierre D ^b   Hanley, David A ^c   Sellmeyer, Deborah ^d   Cheung, Angela M ^e   Shane, Elizabeth ^f   Kearns, Ann ^g   Thomas, Thierry ^h   Boyd, Steven K ^c   Boutroy, Stephanie ^b   Bogado, Cesar ⁱ   Majumdar, Sharmila ^j   Fan, Michelle ^k   Libanati, Cesar ^k   Zanchetta, Jose ⁱ  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY OF CALGARY   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f New York Presbyterian Hospital Columbia University Medical Center   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁱ Instituto de Investigaciones Metabolicas   (Argentina)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k AMGEN INC   (United States)

more..

Author keywords

Alendronate; Cortical thickness; Denosumab; HR PQCT; Volumetric bone mineral density

Indexed keywords

ALENDRONIC ACID; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; PLACEBO; VITAMIN D;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADULT; AGED; AMNESIA; ARTHRALGIA; ARTICLE; BACKACHE; BILIARY COLIC; BONE DENSITY; BONE FRAGILITY; BONE REMODELING; BREAST CANCER; BRONCHITIS; CHOLELITHIASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PNEUMONIA; POSTMENOPAUSE; RADIUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TIBIA; TRABECULAR BONE; UPPER ABDOMINAL PAIN; UTERINE CERVIX CARCINOMA;

AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DEMOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; RANK LIGAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953715717     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.81     Document Type: Article

References (29)

1. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003;14:S13-18.
2. Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-2261.
3. Augat P, Schorlemmer S. The role of cortical bone and its microstructure in bone strength. Age Ageing. 2006;35:S27-31.
4. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone. 2003;32:468-473. (Pubitemid 39665705)
5. Sornay-Rendu E, Boutroy S, Munoz F, et al. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2007;22:425-433.
6. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92: 3076-3081.
7. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-2026.
8. Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097-2104. (Pubitemid 41698773)
9. Zebaze RM, Seeman E. Cortical stability of the femoral neck and hip fracture risk. Lancet. 2005;366: 1523; author reply 1524-1525.
10. Ominsky MS, Li X, Tan HL, et al. The effects of alendronate or denosumab on cortical and trabecular bone mass, bone strength, and bone mass-strength relationships in mice. Abstract 1139. J Bone Miner Res. 2008;23(Suppl1):S40.
11. Ominsky MS, Smith SY, Jolette J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover and increased cancellous and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Calcif Tissue Int. 2008;82(Suppl 1):S240.
12. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-161.
13. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25: 72-81.
14. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22:1832-1841.
15. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831.
16. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43: 222-229.
17. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. (Pubitemid 23261108)
18. Boutroy S, Bouxsein ML, Munoz F, et al. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90:6508-6515.
19. MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys. 2007;29:1096-1105. (Pubitemid 350052626)
20. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000; 15:1526-1536. (Pubitemid 30484522)
21. Reid I, Benhamou L, Bolognese M, et al. Effects of denosumab on bone histology and histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2009;24(Suppl 1):S9.
22. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
23. Vanderoost J, Jaecques S, Van der Perre G, et al. Resorption cavity depth explains strength enhancing effect of antiresorptive agents. J Bone Miner Res. 2009;24(Suppl 1):S157.
24. Reid I, Cornish J, Callon K, et al. Risedronate is preferentially deposited in trabecular bone in rats. J Bone Miner Res. 2009;24(Suppl 1):S353.
25. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care. 1998;6:329-337.
26. Ominsky MS, Schroeder J, Smith SY, et al. Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass and density in aged ovariectomized cynomologus monkeys. J Bone Miner Res. 2006;21(Suppl 1):1272.
27. Ominsky MS, Smith SY, Vlasseros F, et al. Transition from alendronate to denosumab in ovariectomized cynomolgus monkeys maintained or improved cortical and trabecular bone mass, without altering the linear relationship between bone mass and bone strength. J Bone Miner Res. 2008;23(Suppl 1):S22.
28. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124.
29. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.